![]() |
|||
Epzicom (lamivudine/3TC + abacavir)August 2007 View PDF En
español What is Epzicom? Epzicom is marketed by GlaxoSmithKline. It was approved by the US Food and Drug Administration (FDA) for use by people living with HIV in August 2004. Epzicom is a combination of two drugs: 600mg of Ziagen (abacavir) and 300mg of Epivir (lamivudine). Epzicom should be prescribed by a healthcare provider for patients who need both of these drugs. Both of these drugs can still be purchased individually for use in combination with other HIV drugs. In the European Union, the single-tablet combination of Ziagen and Epivir is sold under the brand name Kivexa. Epzicom must be combined with at least one other HIV drug, usually a protease inhibitor (PI) or a non-nucleoside reverse transcriptase inhibitor (NNRTI). GlaxoSmithKline has established a patient assistance program (PAP) for people living with HIV who do not have private or public health insurance and are unable to afford Epzicom. To learn more about the PAP for Epzicom, call 888-825-5249 or refer to GSK's website for more information. For those with private health insurance, GSK has established a program to help cover each Epzicom co-payment, up to $100 every month. To learn more about this co-pay program, check out mysupportcard.com. What is known about Epzicom? Epzicom should not be any more or less effective than Ziagen and Epivir taken as separate pills together. However, it is considered to be a much more convenient way of taking these two anti-HIV drugs. For HIV-positive adults beginning HIV drug therapy for the first time, Epzicom is listed as an "alternative" NRTI option — used in combination with either a protease inhibitor or non-nucleoside reverse transcriptase inhibitor — by the United States Department of Health and Human Services in its treatment guidelines. Tenofovir and emtricitabine, used together as Truvada or as a part of Atripla (efavirenz, tenofovir and emtricitabine), is listed as the "preferred" dual-NRTI option. See the "What is known about ... " sections of Ziagen and Epivir for information about possible drug resistance. What about drug interactions? Epzicom should not be taken at the same time as Emtriva or Truvada (containing Viread and Emtriva). This is because the Epivir in Epzicom is very similar to Emtriva, and it is not believed that combining these two HIV drugs will make a regimen any more effective against the virus. Similarly, Epzicom should not be taken at the same time as Ziagen, Epivir, or Trizivir (containing Ziagen, Epivir and Retrovir). See the "What about drug interactions?" sections of Ziagen and Epivir to learn about possible drug interactions. What about side effects? An inexpensive laboratory test is available to look for an inherited gene, called HLA-B*5701, that has been linked to the hypersensitivity reaction in HIV-positive people taking Epzicom. While not all people with this gene experience an allergic reaction while taking Epzicom, most do. In turn, if you are tested and found to have this gene, Epzicom (or other medications containing abacavir) should either be avoided or used with caution. If you and your doctor are thinking about starting Epzicom or another abacavir-containing medication for the first time, be sure to discuss this genetic test. Lactic acidosis, which can be fatal, and severe liver problems have been reported in people taking nucleoside reverse transcriptase inhibitors (NRTIs), including Ziagen and Epivir, the two active drugs in Epzicom. Contact your doctor immediately if you experience nausea, vomiting, or unusual or unexpected stomach discomfort; weakness and tiredness; shortness of breath; weakness in the arms and legs; yellowing of the skin or eyes; or pain in the upper stomach area. HIV drug regimens containing nucleoside reverse transcriptase inhibitors (NRTIs), including Epzicom, can cause increased fat levels (cholesterol and triglycerides) in the blood, abnormal body-shape changes (lipodystrophy; including increased fat around the abdomen, breasts, and back of the neck, as well as decreased fat in the face, arms, and legs), and diabetes. Taking medications like Epzicom that contain Ziagen may increase the risk of a heart attack. The reason for the increased risk associated with Ziagen, compared with other NRTIs, has not been established. The risk of a heart attack is highest among people living with HIV taking Ziagen who have other cardiovascular disease (CVD) factors, including high blood pressure, high lipids, diabetes, cigarette smoking, family history of CVD. If you have hepatitis B and HIV and plan to stop taking Epzicom, your doctor might want to frequently check your liver enzymes after stopping treatment. This is because the Epivir in Epzicom is also active against the hepatitis B virus (HBV). If Epivir is stopped abruptly, it can cause liver disease to "flare" and damage the liver. See the "What about side effects?" sections of Ziagen and Epivir for additional possible side effects. Can pregnant women take Epzicom? It is not known whether Epzicom passes into breast milk and what effect they may have on a nursing baby. To prevent transmission of the virus to uninfected babies, it is recommended that HIV-positive mothers not breast-feed. What should I tell my doctor before taking Epzicom? Be sure to tell your doctor if you've ever taken Epzicom, Trizivir, or Ziagen in the past. If you stopped these medications in the past because of an allergic reaction, you should not take Epzicom or any medication that contains Ziagen. Tell your doctors and pharmacists about all medicines you take. This includes prescription medications, over-the-counter products, or herbal/natural remedies. Where can I learn more about clinical trials involving
Truvada? Another useful service for finding clinical trials is AIDSinfo.nih.gov, a site run by the US National Institutes of Health. They have "health information specialists" you can talk to at their toll-free number at 1-800-HIV-0440 (1-800-448-0440). |
OTHER LINKS |
||
|
© 2009 Project Inform 1375
Mission Street, San Francisco, CA 94103 415-558-8669 |
|||